A Mackenzie Dreher1, Nitin Arora2, Karen B Fowler3, Zdenek Novak2, William J Britt4, Suresh B Boppana4, Shannon A Ross4. 1. Department of Pediatrics, the University of Alabama at Birmingham, Birmingham, AL. Electronic address: mdreher@peds.uab.edu. 2. Department of Pediatrics, the University of Alabama at Birmingham, Birmingham, AL. 3. Department of Pediatrics, the University of Alabama at Birmingham, Birmingham, AL; Department of Epidemiology, the University of Alabama at Birmingham, Birmingham, AL. 4. Department of Pediatrics, the University of Alabama at Birmingham, Birmingham, AL; Department of Microbiology, the University of Alabama at Birmingham, Birmingham, AL.
Abstract
OBJECTIVE: To evaluate differences in presentation and outcomes in children with symptomatic congenital cytomegalovirus (cCMV) identified on newborn screening (screened group) and those identified based on clinical findings at birth (referred group). STUDY DESIGN: Data on 178 infants with symptomatic cCMV were analyzed. Demographic characteristics, clinical and laboratory findings documented in the nursery, and sequelae data were compared between the screened and the referred groups using χ(2) or Fisher exact test. RESULTS: Two or more clinical findings were detected at birth in 91% of referred infants, and only 58% of screened infants (P < .001). Significantly more children in the referred group had hearing loss compared with screened infants (P = .009). Fifty-one percent of screened children were free of sequelae compared with only 28% of the referred group (P < .003). CONCLUSIONS: Infants with symptomatic cCMV identified based on clinical suspicion have more severe disease at birth and more commonly have sequelae than those identified on newborn screening. Inclusion of referral infants in many previous reports may have overestimated the severity of disease because of selection bias. Defining the complete spectrum of symptomatic disease due to cCMV and providing precise estimates of disease burden can only be gathered from large newborn screening studies.
OBJECTIVE: To evaluate differences in presentation and outcomes in children with symptomatic congenital cytomegalovirus (cCMV) identified on newborn screening (screened group) and those identified based on clinical findings at birth (referred group). STUDY DESIGN: Data on 178 infants with symptomatic cCMV were analyzed. Demographic characteristics, clinical and laboratory findings documented in the nursery, and sequelae data were compared between the screened and the referred groups using χ(2) or Fisher exact test. RESULTS: Two or more clinical findings were detected at birth in 91% of referred infants, and only 58% of screened infants (P < .001). Significantly more children in the referred group had hearing loss compared with screened infants (P = .009). Fifty-one percent of screened children were free of sequelae compared with only 28% of the referred group (P < .003). CONCLUSIONS:Infants with symptomatic cCMV identified based on clinical suspicion have more severe disease at birth and more commonly have sequelae than those identified on newborn screening. Inclusion of referral infants in many previous reports may have overestimated the severity of disease because of selection bias. Defining the complete spectrum of symptomatic disease due to cCMV and providing precise estimates of disease burden can only be gathered from large newborn screening studies.
Authors: D E Noyola; G J Demmler; C T Nelson; C Griesser; W D Williamson; J T Atkins; J Rozelle; M Turcich; A M Llorente; S Sellers-Vinson; A Reynolds; J F Bale; P Gerson; M D Yow Journal: J Pediatr Date: 2001-03 Impact factor: 4.406
Authors: Suresh B Boppana; Shannon A Ross; Zdenek Novak; Masako Shimamura; Robert W Tolan; April L Palmer; Amina Ahmed; Marian G Michaels; Pablo J Sánchez; David I Bernstein; William J Britt; Karen B Fowler Journal: JAMA Date: 2010-04-14 Impact factor: 56.272
Authors: Claire L Townsend; Marianne Forsgren; Karin Ahlfors; Sten-Anders Ivarsson; Pat A Tookey; Catherine S Peckham Journal: Clin Infect Dis Date: 2013-01-18 Impact factor: 9.079
Authors: Lisa B Rivera; Suresh B Boppana; Karen B Fowler; William J Britt; Sergio Stagno; Robert F Pass Journal: Pediatrics Date: 2002-10 Impact factor: 7.124
Authors: Marisa M Mussi-Pinhata; Aparecida Y Yamamoto; Rosângela M Moura Brito; Myriam de Lima Isaac; Patricia F de Carvalho e Oliveira; Suresh Boppana; William J Britt Journal: Clin Infect Dis Date: 2009-08-15 Impact factor: 9.079
Authors: Samar H Ibrahim; Maureen M Jonas; Sarah A Taylor; Luz Helena Gutierrez Sanchez; Jaqueline L Wolf; Shikha S Sundaram Journal: Hepatology Date: 2020-03-18 Impact factor: 17.425
Authors: Nina Reuter; Barbara Kropff; Julia Karin Schneiderbanger; Mira Alt; Adalbert Krawczyk; Christian Sinzger; Thomas H Winkler; William J Britt; Michael Mach; Marco Thomas Journal: J Virol Date: 2020-08-31 Impact factor: 5.103
Authors: Swetha G Pinninti; Mackenzie D Rodgers; Zdenek Novak; William J Britt; Karen B Fowler; Suresh B Boppana; Shannon A Ross Journal: Pediatr Infect Dis J Date: 2016-08 Impact factor: 2.129